NY-AUGURY/GRUNDFOS
Grundfos , a world-leading pump and water technology company, and Augury , a fast-growing data analytics company and leading Digital Machine Health solution provider, are taking a major step toward digitizing water and utility infrastructure worldwide by signing a long-term strategic partnership. Together, they will develop smart diagnostics solutions and services for Grundfos’ customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005113/en/
The two companies have already been working together successfully over the past two years to test new products and service offerings across several markets and industries. Now, they are committing to the next step, offering a range of services and new business models enabled by connected equipment.
“By adding an AI-driven intelligence layer on top of existing assets, we can automatically collect mechanical and operational data, providing actionable machine health insights and diagnostics to our customers and service organisation,” says Tommy Due Høy, Group VP, Global Service & Solutions, Grundfos. He believes the partnership puts down a marker for future solutions.
“When we stand ten, fifteen years from now, this could end up being one of those defining moments where we took a real step forward,” he adds.
Augury works with the world’s largest manufacturers and industrial companies to transform their operations by providing real-time diagnostics regarding the health and performance of their machines. The combination of Augury’s AI-based solutions with Grundfos’ deep applications expertise has the potential to change water delivery and services as we know them.
“Water is at the core of how we live, work, and thrive - yet it often goes unnoticed,” says Saar Yoskovitz, Co-Founder and CEO of Augury. “Through this partnership Grundfos and Augury will work to make water a safer, more available and more useful resource for businesses, individuals and even nations worldwide.”
“We have spent the last eight years working with manufacturers and utilities to ensure that people around the world can always rely on the machines that matter and have seen first-hand the impact it brings. I am thrilled to be partnering with Grundfos to bring this impact to a wider market.”
“Our applications knowledge has consistently been the key differentiator for us to provide best-in-class pumping solutions to the world. As we prepare our portfolio for the future, it is key that we leverage this knowledge base to build more intelligence, IoT, remote monitoring and advanced diagnostics into our offerings to ensure differentiation, which is one of the highest priorities for Grundfos,” said Anupam Bhargava, Group Vice President, Industry at Grundfos.
About Grundfos
Grundfos develops water solutions for the world, setting the standard in terms of innovation, efficiency, reliability, and sustainability. Their solutions help partners and customers move water to where it is supposed to go, providing drinking water for the smallest villages and the highest skyscrapers, treating and removing wastewater and bringing heat and comfort to the world – or cool it down if needed. For the past 75 years, Grundfos’ mission has been to make the highest quality, most reliable equipment.
About Augury
Augury is building a world where people can always rely on the machines that matter. Augury supports its partners by enabling Digital Transformation through superior insights into the health and performance of the machines they use to make products, deliver services and improve lives. To learn more about Augury’s machine health solutions, visit www.augury.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005113/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom